Johnson & Johnson announced plans to spin out its orthopedics business into a standalone company that will retain the DePuy Synthes name, aiming to create a focused competitor to Stryker and Zimmer Biomet. The separation, expected in 18 to 24 months, reflects J&J’s broader strategy to concentrate its medtech portfolio on higher‑growth areas such as cardiovascular, robotic surgery and vision. Management said the ortho unit—generating roughly $9.2 billion in sales in fiscal 2024—will benefit from increased strategic focus and flexibility as an independent entity. J&J named Namal Nawana as worldwide president of DePuy Synthes and signaled further organizational adjustments as part of the move. Analysts flagged the spinout as part of an industry‑wide trend toward portfolio optimization and carve‑outs to unlock shareholder value and sharpen R&D and commercial priorities in medical device markets.